Reprocessing service designed to help hospitals
and vein clinics reduce costs and cut down on medical waste
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies for critical care and surgery, today announced
that more than 200,000 ClosureFast® Catheters have been
successfully reprocessed by the company’s partner, Northeast
Scientific, Inc. (NES), since NES received FDA clearance for
reprocessing the popular vein ablation catheter in 2011.
The ClosureFast® Catheter is one of the most widely used
devices in the United States for performing endovenous treatment of
venous reflux disease, a serious medical condition affecting blood
circulation in the lower legs that causes varicose veins.
“As we approach the sixth anniversary of the launch of our
reprocessing service and mark the attainment of another significant
milestone in the number of ClosureFast® Catheters that have
been successfully reprocessed, we are proud of the exceptional
value this service continues to deliver to our customers,” said
Stewart Strong, President and General Manager of the Interventional
business unit of Teleflex. “The reprocessing service is designed to
help hospitals and vein clinics reduce costs and cut down on
medical waste, objectives that are at the very core of Teleflex’s
commitment to cost-effective healthcare.”
Teleflex is offering the ClosureFast® Catheter
reprocessing service under contract with NES, an established
third-party reprocessor of medical devices. NES received 510(k)
clearance from the U.S. Food and Drug Administration on November
30, 2011 for reprocessing the ClosureFast® Catheter. Since
the reprocessing service was introduced jointly by NES and Vascular
Solutions, Inc. in January 2012, several hundred U.S. hospitals and
vein clinics have enrolled in the program.
“Since Teleflex’s acquisition of Vascular Solutions in February
2017, we have been very pleased to be working in collaboration with
NES. We share the commitment to helping hospitals and vein clinics
reduce costs and cut down on medical waste,” said Strong. “We have
recently augmented the level of customer service for the
ClosureFast® Catheter reprocessing program by introducing an
in-house sales team to support the ongoing efforts of our direct
sales force.”
Craig Allmendinger, Chief Executive Officer of NES, commented,
“We are gratified by the achievements of the ClosureFast®
Catheter reprocessing service. The reprocessed vein ablation
catheters have demonstrated an excellent record for a sustained
period of time and the program has earned the respect of a growing
number of vein clinic practitioners. With Teleflex’s vast
experience in the vein clinic market and its focus on the needs of
its physician customers and patient outcomes, we look forward to
the continued success of the program.”
In addition to offering the reprocessing service for
ClosureFast® Catheters, Teleflex markets a full range of
accessory products that are needed to perform both RF- and
laser-based vein ablation procedures. The company offers procedure
packs designed for either RF or laser procedures, micro-introducers
and 7F micro-HV kits, 0.018” and 0.025” guidewires, 18G echogenic
needles for percutaneous entry, products for administering
tumescent anesthesia, and disposable vein hooks for use in
phlebectomy procedures.
About Northeast Scientific
Northeast Scientific, Inc. (NES), a privately-held company
headquartered in Waterbury, Connecticut, is registered with the
U.S. Food and Drug Administration as both a reprocessor of
single-use medical devices and as a manufacturer. NES recently
relocated to a new 20,000 square-foot facility specifically
designed for its operations. Founded in 2005, NES received its
first 510(k) clearance in 2007 and is developing multiple 510(k)s
for the interventional markets. NES performs all reprocessing and
manufacturing on site and is ISO 13485 registered. NES is not
affiliated with the original equipment manufacturers of the devices
it reprocesses. For more information about NES, visit the company’s
website at www.smarthealth-care.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch® and Weck® – trusted brands united by a common
sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
ClosureFast is a registered trademark of Covidien LP (a
subsidiary of Medtronic plc). Reprocessing of ClosureFast®
Catheters is performed by Northeast Scientific, Inc. and is not
licensed by or affiliated in any way with Covidien, Covidien LP,
VNUS Medical Technologies, Inc., Tyco Healthcare Group, LP, or
Medtronic plc.
Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA,
Pilling, Rüsch, and Weck are trademarks or registered trademarks of
Teleflex Incorporated or its affiliates, in the U.S. and/or other
countries.
© 2018 Teleflex Incorporated. All rights reserved. MC-003836
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180109005353/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024